These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 9141462)

  • 1. Studies of neoplasia in the Min mouse.
    Shoemaker AR; Gould KA; Luongo C; Moser AR; Dove WF
    Biochim Biophys Acta; 1997 Apr; 1332(2):F25-48. PubMed ID: 9141462
    [No Abstract]   [Full Text] [Related]  

  • 2. E-cadherin and adenomatous polyposis coli mutations are synergistic in intestinal tumor initiation in mice.
    Smits R; Ruiz P; Diaz-Cano S; Luz A; Jagmohan-Changur S; Breukel C; Birchmeier C; Birchmeier W; Fodde R
    Gastroenterology; 2000 Oct; 119(4):1045-53. PubMed ID: 11040191
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Action of Min and Mom1 on neoplasia in ectopic intestinal grafts.
    Gould KA; Dove WF
    Cell Growth Differ; 1996 Oct; 7(10):1361-8. PubMed ID: 8891340
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mlh1 deficiency enhances several phenotypes of Apc(Min)/+ mice.
    Shoemaker AR; Haigis KM; Baker SM; Dudley S; Liskay RM; Dove WF
    Oncogene; 2000 May; 19(23):2774-9. PubMed ID: 10851078
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The tumour suppressor APC gene product is associated with cell adhesion.
    Burchill SA
    Bioessays; 1994 Apr; 16(4):225-7. PubMed ID: 8031298
    [No Abstract]   [Full Text] [Related]  

  • 6. Intestinal tumor load in the Min/+ mouse model is not correlated with eicosanoid biosynthesis.
    Whelan J; Chiu CH; McEntee MF
    Adv Exp Med Biol; 1999; 469():607-15. PubMed ID: 10667389
    [No Abstract]   [Full Text] [Related]  

  • 7. The threshold level of adenomatous polyposis coli protein for mouse intestinal tumorigenesis.
    Li Q; Ishikawa TO; Oshima M; Taketo MM
    Cancer Res; 2005 Oct; 65(19):8622-7. PubMed ID: 16204028
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor-associated Apc mutations in Mlh1-/- Apc1638N mice reveal a mutational signature of Mlh1 deficiency.
    Kuraguchi M; Edelmann W; Yang K; Lipkin M; Kucherlapati R; Brown AM
    Oncogene; 2000 Nov; 19(50):5755-63. PubMed ID: 11126362
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Response of Apc(min) and A33 (delta N beta-cat) mutant mice to treatment with tea, sulindac, and 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP).
    Orner GA; Dashwood WM; Blum CA; Díaz GD; Li Q; Al-Fageeh M; Tebbutt N; Heath JK; Ernst M; Dashwood RH
    Mutat Res; 2002 Sep; 506-507():121-7. PubMed ID: 12351151
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Suppression of intestinal and mammary neoplasia by lifetime administration of aspirin in Apc(Min/+) and Apc(Min/+), Msh2(-/-) mice.
    Sansom OJ; Stark LA; Dunlop MG; Clarke AR
    Cancer Res; 2001 Oct; 61(19):7060-4. PubMed ID: 11585736
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Use of Apc(Min/+) mouse model in the studies of intestinal tumors].
    Sheng HQ; Chen J; Lai MD
    Yi Chuan; 2008 Mar; 30(3):277-82. PubMed ID: 18331993
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Liposome-mediated adenomatous polyposis coli gene therapy: a novel anti-adenoma strategy in multiple intestinal neoplasia mouse model.
    Lee J; Hargest R; Wasan H; Phillips RK
    Dis Colon Rectum; 2004 Dec; 47(12):2105-13. PubMed ID: 15657662
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oncogenic targets of beta-catenin-mediated transcription in molecular pathogenesis of intestinal polyposis.
    Watson SA
    Lancet; 2001 Feb; 357(9256):572-3. PubMed ID: 11558478
    [No Abstract]   [Full Text] [Related]  

  • 14. Adenomatous polyposis coli gene as a gatekeeper.
    Nakayama T; Morishita T; Kamiya T
    Rev Gastroenterol Peru; 2002; 22(2):164-7. PubMed ID: 12098745
    [TBL] [Abstract][Full Text] [Related]  

  • 15. R-flurbiprofen chemoprevention and treatment of intestinal adenomas in the APC(Min)/+ mouse model: implications for prophylaxis and treatment of colon cancer.
    Wechter WJ; Kantoci D; Murray ED; Quiggle DD; Leipold DD; Gibson KM; McCracken JD
    Cancer Res; 1997 Oct; 57(19):4316-24. PubMed ID: 9331093
    [TBL] [Abstract][Full Text] [Related]  

  • 16. APC and intestinal carcinogenesis. Insights from animal models.
    Bertagnolli MM
    Ann N Y Acad Sci; 1999; 889():32-44. PubMed ID: 10668480
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of intestinal tumors by curcumin is associated with changes in the intestinal immune cell profile.
    Churchill M; Chadburn A; Bilinski RT; Bertagnolli MM
    J Surg Res; 2000 Apr; 89(2):169-75. PubMed ID: 10729246
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rapamycin inhibits oncogenic intestinal ion channels and neoplasia in APC(Min/+) mice.
    Koehl GE; Spitzner M; Ousingsawat J; Schreiber R; Geissler EK; Kunzelmann K
    Oncogene; 2010 Mar; 29(10):1553-60. PubMed ID: 19966863
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemoprevention of intestinal polyposis in the Apcdelta716 mouse by rofecoxib, a specific cyclooxygenase-2 inhibitor.
    Oshima M; Murai N; Kargman S; Arguello M; Luk P; Kwong E; Taketo MM; Evans JF
    Cancer Res; 2001 Feb; 61(4):1733-40. PubMed ID: 11245490
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemoprevention of intestinal tumorigenesis by nabumetone: induction of apoptosis and Bcl-2 downregulation.
    Roy HK; Karoski WJ; Ratashak A; Smyrk TC
    Br J Cancer; 2001 May; 84(10):1412-6. PubMed ID: 11355956
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.